Capitalizing on Biotech Rebound with Leveraged ETFs
April 18, 2016 at 14:48 PM EDT
Biotechnology stocks remain one of worst performing areas that are still stuck in a bear market after failing to recuperate earlier losses in the year, along with the broader market. However, exchange traded fund (ETF) investors still believe in a rebound. The iShares Nasdaq Biotechnology ETF...